Research · 2025-03-01
Kratom Leaf Extracts Lower Cholesterol Through PCSK9 and LDLR Pathways in Lab Study
Source: Scientific Reports (Nature)
Why it matters
Cardiovascular disease remains the leading cause of death globally, and elevated LDL cholesterol is a primary risk factor. This first-of-its-kind study identifies a molecular mechanism by which kratom compounds could lower cholesterol—potentially pointing toward novel supplement or drug applications, though human trials are needed.
The big picture
Kratom users in Southeast Asia have historically shown lower cholesterol levels than non-users, but the molecular mechanism was unknown. PCSK9 inhibitors are among the most effective cholesterol drugs available but are expensive injectable medications. This study from Thailand's Walailak University examined whether kratom leaf extracts from red-vein and white-vein strains could work through the same PCSK9/LDLR pathway in human liver cells (HepG2)—potentially offering a less expensive natural alternative.
Key findings
- Kratom leaf extracts from both red-vein and white-vein strains significantly increased LDLR protein expression (2.1-2.2 fold) in liver cells
- Both strains significantly decreased PCSK9 protein expression by 70-77%
- LDL uptake into cells increased approximately 2.6-2.9 fold with kratom treatment
- Mitragynine alone showed PCSK9-inhibiting and LDLR-upregulating activity
- Molecular docking showed mitragynine has stronger binding affinity for LDLR's EGF-A domain (-7.57 kcal/mol) than atorvastatin (-5.37 kcal/mol)
- Key bioactive compounds identified: mitragynine, quercetin, and rutin
What they say
The authors concluded: "Kratom leaf extracts from red-vein and white-vein strains possessed hypolipidaemic effects by decreased PCSK9 expression and increased LDLR expression through the modulation of SREBP2 and HNF-1α. Therefore, kratom could serve as a potential supplement for ameliorating hypercholesterolemia."
Bottom line
A peer-reviewed lab study identifies a specific cholesterol-lowering mechanism in kratom—via PCSK9 inhibition similar to expensive injectable drugs—but human trials are needed before any clinical conclusions can be drawn.